TY - JOUR T1 - Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060). AU - Rajan,Kumar B, AU - Weuve,Jennifer, AU - Barnes,Lisa L, AU - McAninch,Elizabeth A, AU - Wilson,Robert S, AU - Evans,Denis A, Y1 - 2021/05/27/ PY - 2021/03/29/revised PY - 2020/10/11/received PY - 2021/04/05/accepted PY - 2021/5/28/pubmed PY - 2022/2/11/medline PY - 2021/5/27/entrez KW - 2020 US prevalence KW - clinical Alzheimer's disease KW - forecasting KW - mild cognitive impairment SP - 1966 EP - 1975 JF - Alzheimer's & dementia : the journal of the Alzheimer's Association JO - Alzheimers Dement VL - 17 IS - 12 N2 - INTRODUCTION: The estimate of people with clinical Alzheimer's disease (AD) and mild cognitive impairment provides an understanding of the disease burden. METHODS: We estimated people with cognitive impairment using a quasibinomial regression model in 10,342 participants with cognitive test scores. RESULTS: The 2020 US Census-adjusted prevalence of clinical AD was 11.3% (95% confidence interval [CI] = 10.7-11.9): 10.0% among non-Hispanic Whites, 14.0% among Hispanics, and 18.6% among non-Hispanic Blacks. We estimate that in 2020, 6.07 (95% CI = 5.75-6.38) million people were living with clinical AD, which increases to 13.85 (95% CI = 12.98-14.74) million in 2060, 423% higher among Hispanics, 192% higher among Blacks, and 63% higher among Whites. However, there are predicted to be more significant increases in later years among those over 85 and women compared to men. DISCUSSION: The number of people with clinical AD will increase as the "baby boom" generation reaches older ages, exerting a strong upward influence on disease burden. SN - 1552-5279 UR - https://www.unboundmedicine.com/medline/citation/34043283/full_citation DB - PRIME DP - Unbound Medicine ER -